首页> 美国卫生研究院文献>Clinical and Molecular Allergy : CMA >Bilastine: new insight into antihistamine treatment
【2h】

Bilastine: new insight into antihistamine treatment

机译:Bilastine:抗组胺药治疗的新见解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bilastine is a new second generation H1-antihistamine recently approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU). Bilastine epitomizes the evolution of research on antihistamines concerning both efficacy and safety. In AR treatment, a number of large controlled clinical trials documented its efficacy, as assessed by improvement of all nasal and ocular symptoms and quality of life. These outcomes show that bilastine meets current EAACI/ARIA criteria for medications used in the treatment of AR. Also in CU, the review of the literature indicates that once-daily treatment with bilastine 20 mg was effective in managing symptoms and improving patient’s quality of life. Concerning safety and tolerability, the profile of bilastine is very similar to placebo and in particular the adverse effects on central nervous system are insignificant. The balance of efficacy and safety of bilastine is particularly helpful when dosages higher than standard are needed to control the symptoms, as frequently occurs in patients with urticaria, in whom antihistamines doses up to four times the standard dose may be administered.
机译:Bilastine是一种新的第二代H1-抗组胺药,最近被批准用于对症性鼻炎(AR)和慢性荨麻疹(CU)的对症治疗。 Bilastine概括了抗组胺药在功效和安全性方面的研究进展。在AR治疗中,许多大型对照临床试验证明了其功效,通过改善所有鼻和眼症状以及生活质量来评估。这些结果表明,比拉司汀符合目前用于治疗AR的药物的EAACI / ARIA标准。同样在CU,对文献的回顾表明,每天一次用比拉汀20 mg治疗可有效控制症状并改善患者的生活质量。关于安全性和耐受性,比拉汀的概况与安慰剂非常相似,特别是对中枢神经系统的不良影响微不足道。当需要使用比标准剂量更高的剂量来控制症状时,如在荨麻疹患者中经常发生的情况中,Bilastine的有效性和安全性之间的平衡特别有用,在这种患者中,抗组胺药的剂量最多可为标准剂量的四倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号